Drugmaker Gilead Sciences Inc. said Tuesday that its third-quarter profit rose 17 percent on higher sales of its best-selling HIV drugs. Net income was $788.6 million, or 47 cents per share, in the July-September ...
Scooped by
Matt Skallerud
onto Health, HIV & Addiction Topics in the LGBTQ+ Community |